OBR Daily Commentary

forumImage

Trastuzumab Deruxtecan Demonstrated Clinically-Meaningful Response In Patients With Refractory HER2-positive Metastatic Breast Cancer, A Population With High Unmet Need

(AstraZeneca) May 8, 2019 - AstraZeneca and Daiichi Sankyo Company, Limited today announced positive top-line results for the pivotal Phase II DESTINY-Breast01 trial of trastuzumab deruxtecan (DS-8201). The HER2-targeting antibody drug conjugate (ADC) and potential new medicine was evaluated in patients with HER2-positive, unresectable and/or metastatic breast cancer previously treated with trastuzumab emtansine.

Read Article arrow

Dean Gesme, MD (Posted: May 08, 2019)

quotesThe expansion of antibody drug conjugates may have more "real world" benefit for our patients than CART cells. We are also in need of expanding our anti-Her2 breast cancer armamentarium and this agent may prove active in IHC 1+ breast cancers as well!quotes

Add Comment 2 Comment
forumImage

They’re The Next New Thing In Cancer Immunotherapy, But Will Bispecifics Help More Patients Than CAR-Ts?

(STAT Plus) Feb 27, 2019 - In cancer immunotherapy these days, technology is advancing so fast that 2017’s buzzy new treatment may soon be passe: Only 18 months after approval of the first CAR-T, pharmaceutical companies and biotechs are already talking about next-generation cancer therapy.

Read Article arrow

Dean Gesme, MD (Posted: February 27, 2019)

quotesBITE technology is extremely exciting! It will be important to see if the first product launches can avoid the extreme complexity and exorbitant total expense that has become a huge impediment to the implementation of CART therapies.quotes

Add Comment 1 Comment
forumImage

Reducing Time to Chemo Administration in an Inpatient Hematology Malignancy Unit

(Journal of Clinical Pathways) Sept 25, 2018 - Researchers from a US hospital were able to reduce the time to chemotherapy administration for elective admissions by over 64% in an inpatient hematology malignancy unit.

Read Article arrow

Dean Gesme, MD (Posted: September 25, 2018)

quotesIn contrast, chemotherapy initiation in the outpatient setting is being continually delayed due to prior authorization of testing and treatment along with formulary restrictions and now step therapy requirements.quotes

Add Comment 1 Comment

Meet the Editorial Board

Prostate Cancer
member photo
Tomasz M. Beer, MD, FACP

Professor of Medicine, Division of Hematology/Medical O...

Community Oncology
member photo
Dean Gesme, MD

FACP FACPE FASCO President, Minnesota Oncology...

Breast Cancer
member photo
Debu Tripathy, MD

Professor and Chair, Department of Breast Medical Oncol...

Lung Cancer
member photo
H. Jack West, MD

Medical Director, Thoracic Oncology Program, Swedish Ca...

Gastrointestinal Cancers
member photo
Howard S. Hochster, MD

Distinguished Professor of Medicine, Rutgers Robert Woo...

Radiation Oncology
member photo
Howard Sandler, MD, MS, FASTRO

Ronald H. Bloom Chair in Cancer Therapeutics
Pr...

Community Oncology
member photo
Jeff Patton, M.D.

CEO Tennessee Oncology...

Precision Medicine Section Editor
member photo
Jennifer Levin Carter, MD, MPH

Chief Medical Officer and Founder, N-of-One...

Financial Sector
member photo
Michael G. King Jr.

Managing Director and Senior Biotechnology Analyst...

Gastrointestinal Cancers
member photo
Richard Goldberg, MD

Director WVU Cancer Institute Director of Cancer Signa...

Editor-In-Chief
member photo
Robert A. Figlin, MD., FACP

Professor and Director, Division of Hematology Oncology...

Health Policy
member photo
Ted Okon

Executive Director Community Oncology Alliance...

Community Oncology
member photo
Thomas Marsland, MD

Vice President Integrated Community Oncology Network ...

Community Oncology
member photo
William Harwin MD

Florida Cancer Specialists President and Managing Part...

Health Policy
member photo
William McGivney, PhD

National Health Policy Expert...

Payer
member photo
Winston Wong, PharmD

President, W-Squared Group...